Patents by Inventor Ziping Yang

Ziping Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
    Publication number: 20240075154
    Abstract: An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 7, 2024
    Inventors: Bing XIA, Yuhong ZHOU, Ziping WEI, Jianfeng YANG
  • Hemostatic compositions
    Patent number: 9833541
    Abstract: The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 17.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 5, 2017
    Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Jill McCoy, Joseph F. Dwyer, Ziping Yang
  • HEMOSTATIC COMPOSITIONS
    Publication number: 20160354511
    Abstract: The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 17.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 8, 2016
    Inventors: Jill McCoy, Joseph F. Dwyer, Ziping Yang
  • Multi-lectin affinity chromatography and uses thereof
    Publication number: 20090166224
    Abstract: Methods, compositions, and kits related to the use of multi-ligand affinity chromatography are described. The methods include those related to identification of glycoprotein panels for analyzing and diagnosing disease.
    Type: Application
    Filed: May 5, 2005
    Publication date: July 2, 2009
    Inventors: Ziping Yang, William S. Hancock, Marina Hincapie
  • NOVEL SEQUENCE VARIANTS OF MULTI-DRUG RESISTANCE GENES, MDR1 AND MRP1, AND RECOMBINANT CELLS EXPRESSING MRP1 AND MDR1 FOR ASSESSMENT OF DRUG PENETRATION AND DISPOSITION
    Publication number: 20090130701
    Abstract: Provided are compositions relating to novel MDR1 polymorphisms, including nucleic acids, polypeptides, and recombinant cells, as well as methods for detection of MDR1 polymorphisms in biological samples and elucidation of the influence of MDR1 polymorphisms on MDR1 protein function. Also provided are a rat MRP1 cDNA and protein, stable cell lines expressing the rat MRP1 protein, and methods of assessing drug penetration or disposition in a cell line expressing a recombinant mammalian MRP1 or MDR1 protein, or a homolog thereof.
    Type: Application
    Filed: September 26, 2008
    Publication date: May 21, 2009
    Applicant: WASHINGTON, UNIVERSITY OF
    Inventors: Rodney J.Y. Ho, Ziping Yang, Danny D. Shen, Daniel Wu
  • Sequence variants of multi-drug resistance genes, MDR1 and MRP1, and methods for assessment of drug penetration and disposition
    Patent number: 7445897
    Abstract: Provided are compositions relating to novel MDR1 polymorphisms, including nucleic acids, polypeptides, and recombinant cells, as well as methods for detection of MDR1 polymorphisms in biological samples and elucidation of the influence of MDR1 polymorphisms on MDR1 protein function. Also provided are a rat MRP1 cDNA and protein, stable cell lines expressing the rat MRP1 protein, and methods of assessing drug penetration or disposition in a cell line expressing a recombinant mammalian MRP1 or MDR1 protein, or a homolog thereof.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: November 4, 2008
    Assignee: University of Washington
    Inventors: Rodney J. Y. Ho, Ziping Yang, Danny D. Shen, Daniel Wu
  • Novel sequence variants of multi-drug resistance genes, MDR1 and MRP1, and recombinant cells expressing MRP1 and MDR1 for assessment of drug penetration and disposition
    Publication number: 20060024685
    Abstract: Provided are compositions relating to novel MDR1 polymorphisms, including nucleic acids, polypeptides, and recombinant cells, as well as methods for detection of MDR1 polymorphisms in biological samples and elucidation of the influence of MDR1 polymorphisms on MDR1 protein function. Also provided are a rat MRP1 cDNA and protein, stable cell lines expressing the rat MRP1 protein, and methods of assessing drug penetration or disposition in a cell line expressing a recombinant mammalian MRP1 or MDR1 protein, or a homolog thereof.
    Type: Application
    Filed: January 26, 2005
    Publication date: February 2, 2006
    Applicant: University of Washington, Office of Technology Licensing
    Inventors: Rodney Ho, Ziping Yang, Danny Shen, Daniel Wu